Differentiated Thyroid Cancer with a Focus on Adverse Event Management

January 21, 2021
Targeted Oncology

Steven Sherman, MD, FACE, provides insight on the treatment of radioactive iodine-refractory differentiated thyroid cancer and the management of adverse events.